ClinicalTrials.gg
CompletedNCT03426605Updated May 3, 2024Results posted

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

A Phase 1 interventional study of Open Label LAM-003 in Oncology and Acute Myeloid Leukemia, sponsored by OrphAI Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-03.

Primary conditionLeukemia, Myeloid, AcuteRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's listed conditions name Leukemia, Myeloid, Acute, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by OrphAI Therapeutics · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,394th of 1,908
17 · median 35
Started
2018
with 98 others
Phase 1
772 of 2,138
127 open now
Registered
1,429th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,394th largest by enrollment of the 1,908 interventional ones that give a count, is one of 99 that started in 2018, is one of 772 in phase 1, and was the 1,429th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia

Read the detailed description

This clinical trial is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of LAM-003 across a range of LAM-003 dose levels when administered to subjects with previously treated relapsed or refractory cute Myeloid Leukemia (AML).

Subjects will self-administer oral LAM-003 either once or twice per day as long as they are safely benefitting from therapy. Cohorts of 3 to 6 subjects will be sequentially enrolled at progressively higher dose levels of LAM-003 using a standard 3+3 dose-escalation design. Based on the pattern of dose-limiting toxicities observed in the first 4 weeks of therapy, escalation will proceed to define a recommended LAM-003 dosing regimen.

03

Conditions studied

  • Oncology
  • Acute Myeloid Leukemia

Browse trials for

04

In context

Leukemia, Myeloid, Acute Reclassified

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

This study's enrollment of 17 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

OrphAI Therapeutics is the lead sponsor of 4 studies on the registry; none are open to participants now.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women of age ≥18 years.
  2. (ECOG) performance status of 0, 1, or 2.
  3. Presence of measurable AML that has progressed during or after prior therapy
  4. All acute toxic effects of any prior antitumor therapy resolved to Grade 1.
  5. Adequate hepatic profile.
  6. Adequate renal function.
  7. Adequate coagulation profile.
  8. Negative antiviral serology for (HIV), , and .
  9. For female subjects of , a negative serum pregnancy test.
  10. For both male and female subjects, willingness to use adequate .
  11. Willingness and ability of the subject to comply with study activities.
  12. Evidence of a personally signed document.

Exclusion criteria

Exclusion Criteria:

  1. Leukemic blast cell count >50 × 10\^9/L before the start of study therapy and despite the use hydroxyurea, cytarabine, and/or cyclophosphamide.
  2. Presence of known central nervous system (CNS) leukemia.
  3. Presence of another major cancer.
  4. Ongoing Grade >1 proliferative or nonproliferative retinopathy.
  5. Significant cardiovascular disease or abnormalities.
  6. Significant gastrointestinal disease
  7. Uncontrolled ongoing infection.
  8. Pregnancy or breastfeeding.
  9. Major surgery within 4 weeks before the start of study therapy.
  10. Subject was a candidate for hematopoietic stem cell transplantation ().
  11. Ongoing severe graft-versus-house disease () with Grade ≥2 serum , Grade ≥3 skin involvement, or Grade ≥3 diarrhea at the start of study therapy.
  12. Prior solid organ transplantation.
  13. Ongoing therapy other than .
  14. Use of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4.
  15. Use of a drug known to prolong the cardiac .
  16. Concurrent participation in another therapeutic or imaging clinical trial.
  17. Presence of a concomitant medical condition that (in the judgement of the investigator) interferes with the ability of the subject to participate in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    LAM-003

    Open label LAM-003 at three sequentially increasing starting dose levels of 200, 300 and 450 mg.

    Drug: Open Label LAM-003

Interventions

  • DrugOpen Label LAM-003

    LAM-003

07

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    A primary objective was to determine the LAM-003 MTD and/or recommended dosing regimen (RDR) based on the pattern of dose-limiting toxicities (DLTs) in Cycle 1 of therapy. MTD as determined by DLTs.

    Time frame: At the end of the 28-day observation period for Cycle 1.

Secondary outcomes

  1. Adverse Event Assessment

    Number and percentage of participants with an adverse event (AE).

    Time frame: Weekly during the first 4 weeks and then every 4 weeks for up to 48 weeks.

  2. Maximum Plasma Concentration (Cmax)

    The pharmacokinetic parameter Cmax was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug)

    Time frame: Cycle 1 Days 1, 2 and 8 (1 cycle = 28 days)

  3. Time of Maximum Concentration [Tmax]

    The pharmacokinetic parameter Tmax was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug)

    Time frame: Cycle 1 Days 1, 2 and 8 (1 cycle = 28 days)

  4. Area Under the Curve [AUC]

    The pharmacokinetic parameter area under the concentration-time curve was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug). AUClast is the area under the concentration-time curve from time-zero to the time of the last quantifiable concentration. AUCtau is the area under the concentration-time curve during the dosing interval where tau=24hours for once daily (QD) dosing. AUCtau was not calculated for LAM-003.

    Time frame: Cycle 1 Days 1, 2 and 8 (1 cycle = 28 days)

  5. Objective Response Rate

    Tumor response by AML response criteria (Cheson 2003).

    Time frame: Every 8 to 12 weeks for up to 48 weeks.

  6. Event-Free Survival (EFS) and Overall Survival (OS)

    Event-free survival (EFS), defined as the interval from the start of study therapy to the earliest of the first documentation of disease relapse, disease progression, treatment failure (TF), or death from any cause. Overall survival (OS), defined as the interval from the start of study therapy to death from any cause.

    Time frame: Every 8 to 12 weeks for up to 48 weeks.

08

Results

Posted May 3, 2024

Participant flow

This study was conducted by 6 investigators located in medical centers throughout the United States.

Participant flow — Overall Study
MilestoneLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QD
Started6344
Completed0000
Not completed6344
Withdrew: Aml relapse or progression2122
Withdrew: Treatment failure3200
Withdrew: Adverse event1011
Withdrew: Withdrawal by subject0011

Outcome measures

PrimaryMaximum Tolerated Dose (MTD)

A primary objective was to determine the LAM-003 MTD and/or recommended dosing regimen (RDR) based on the pattern of dose-limiting toxicities (DLTs) in Cycle 1 of therapy. MTD as determined by DLTs.

Time frame:
At the end of the 28-day observation period for Cycle 1.
Reported as:
Number · DLTs
Maximum Tolerated Dose (MTD)
DLTsLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QD
Maximum Tolerated Dose (MTD)0000
SecondaryAdverse Event Assessment

Number and percentage of participants with an adverse event (AE).

Time frame:
Weekly during the first 4 weeks and then every 4 weeks for up to 48 weeks.
Reported as:
Count of participants · Participants
Adverse Event Assessment
ParticipantsLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QD
With ≥1 AE6344
With ≥1 TEAE6344
With ≥1 study-drug-related TEAE3212
With ≥1 TEAE of Grade ≥35343
With ≥1 study-drug-related TEAE of Grade ≥30000
With ≥1 SAE3332
With ≥1 treatment-emergent SAE3332
With ≥1 study-drug-related treatment-emergent SAE0000
With ≥1 AESI0000
With AEs resulting in drug interruption of study drug0010
With AEs (other than AML progression) resulting in permanent discontinuation of study drug1001
With AEs resulting in death within 30 days from the last dose of study drug1121
SecondaryMaximum Plasma Concentration (Cmax)

The pharmacokinetic parameter Cmax was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug)

Time frame:
Cycle 1 Days 1, 2 and 8 (1 cycle = 28 days)
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax)
ng/mLLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QD
LAM-003A Day 13550 ± 18608360 ± 223091708240 ± 3750
LAM-003A Day 85000 ± 5768360 ± 115085009620 ± 3810
LAM-003 Day 10.560 ± 0.3201.47 ± 1.282.711.83 ± 1.30
LAM-003 Day 80.617 ± 0.2201.08 ± 1.363.601.45 ± 1.43
SecondaryTime of Maximum Concentration [Tmax]

The pharmacokinetic parameter Tmax was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug)

Time frame:
Cycle 1 Days 1, 2 and 8 (1 cycle = 28 days)
Reported as:
Median · hours
Time of Maximum Concentration [Tmax]
hoursLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QD
LAM-003A for Day 13.80 (1.00 to 4.00)3.80 (1.80 to 4.00)4.10 (4.10 to 4.10)1.95 (1.90 to 23.3)
LAM-003A for Day 82.00 (1.80 to 4.00)4.00 (4.00 to 5.80)2.10 (2.10 to 2.10)1.95 (1.10 to 2.00)
LAM-003 for Day 11.00 (0.50 to 1.00)1.80 (0.80 to 2.00)0.50 (0.50 to 0.50)0.50 (0.40 to 1.00)
LAM-003 for Day 80.75 (0.50 to 1.00)1.10 (0.50 to 1.10)0.50 (0.50 to 0.50)1.10 (0.600 to 3.00)
SecondaryArea Under the Curve [AUC]

The pharmacokinetic parameter area under the concentration-time curve was determined in plasma for the active metabolite of LAM-003A and LAM-003 (prodrug). AUClast is the area under the concentration-time curve from time-zero to the time of the last quantifiable concentration. AUCtau is the area under the concentration-time curve during the dosing interval where tau=24hours for once daily (QD) dosing. AUCtau was not calculated for LAM-003.

Time frame:
Cycle 1 Days 1, 2 and 8 (1 cycle = 28 days)
Reported as:
Mean · h*ng/mL
Area Under the Curve [AUC]
h*ng/mLLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QD
LAM-003A AUClast for Day 143100 ± 23200112000 ± 45100131000105000 ± 39800
LAM-003A AUClast for Day 824400 ± 568053600 ± 104005280056400 ± 18000
LAM-003 AUClast for Day 10.287 ± 0.2540.958 ± 0.7451.720.935 ± 1.10
LAM-003 AUClast for Day 80.383 ± 0.3111.18 ± 1.840.900.833 ± 0.837
LAM-003A AUCtau for Day 126000 ± 43900113000 ± 46100132000110000 ± 47300
LAM-003A AUCtau for Day 842300 ± 4840—113000103000 ± 33900
SecondaryObjective Response Rate

Tumor response by AML response criteria (Cheson 2003).

Time frame:
Every 8 to 12 weeks for up to 48 weeks.
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QD
CRc: Composite complete remission including participants with CR, CRMRD-, and CRi0000
Partial Response0000
Treatment Failure3123
Disease Relapse or Progression2221
Nonevaluable1000
SecondaryEvent-Free Survival (EFS) and Overall Survival (OS)

Event-free survival (EFS), defined as the interval from the start of study therapy to the earliest of the first documentation of disease relapse, disease progression, treatment failure (TF), or death from any cause. Overall survival (OS), defined as the interval from the start of study therapy to death from any cause.

Time frame:
Every 8 to 12 weeks for up to 48 weeks.
Reported as:
Median · months
Event-Free Survival (EFS) and Overall Survival (OS)
monthsLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QD
EFS0.6 (0.1 to 1.9)0.9 (0.7 to 1.2)1.8 (0.3 to 3.5)1.5 (0.6 to 2.9)
OS3 (0.3 to 3.2)5.1 (1.0 to 5.9)3.4 (0.8 to 5.5)3.1 (1.6 to 4.3)

Adverse events

Collected over Adverse Events were collected from the signing of informed consent through to 30 days after the final dose of study drug administration or when any ongoing drug-related AEs and/or serious adverse events (SAEs) have resolved or become stable (up to Week 48).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LAM-003 200 mg QD2/6 (33.3%)3/6 (50%)6/6 (100%)
LAM-003 300 mg QD1/3 (33.3%)3/3 (100%)3/3 (100%)
LAM-003 450 mg QD2/4 (50%)3/4 (75%)4/4 (100%)
LAM-003 600 mg QD1/4 (25%)2/4 (50%)4/4 (100%)
LAM-003 750 mg QD2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDLAM-003 750 mg QD
PyrexiaGeneral disorders0/61/30/40/42/3
Febrile NeutropeniaBlood and lymphatic system disorders0/62/31/40/40/3
Disease ProgressionGeneral disorders1/61/32/41/40/3
Cerebral HemorrhageNervous system disorders0/60/30/40/41/3
Pneumonia bacterialInfections and infestations0/60/30/40/41/3
Hemoglobin DecreasedInvestigations0/60/30/41/40/3
Diabetic ketoacidosisMetabolism and nutrition disorders0/60/30/41/40/3
WBC Count IncreasedInvestigations1/60/30/40/40/3
Hemorrhage IntracranialNervous system disorders1/60/30/40/40/3
Most frequent other events
Showing 10 of 109
Most frequent other events
EventLAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDLAM-003 750 mg QD
CoughRespiratory, thoracic and mediastinal disorders1/63/30/41/41/3
Oedma peripheralGeneral disorders3/62/30/41/41/3
ChillsGeneral disorders1/62/31/41/40/3
Non-cardiac chest painGeneral disorders0/62/31/40/40/3
DiarrhoeaGastrointestinal disorders3/61/31/40/42/3
VomitingGastrointestinal disorders1/62/31/41/41/3
Platelet count decreasedInvestigations4/60/31/40/40/3
White blood cell count increasedInvestigations4/60/30/40/40/3
Pain in extremityMusculoskeletal and connective tissue disorders0/62/31/41/42/3
EpistaxisRespiratory, thoracic and mediastinal disorders2/62/31/41/40/3

Baseline characteristics

The study population was generally consistent with the epidemiology of AML.

Age, Continuous
Age, Continuous(years)LAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDTotal
Median71 (39 to 82)34 (26 to 65)75 (54 to 83)67.5 (48 to 73)68 (26 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)LAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDTotal
Female21216
Male422311
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDTotal
Hispanic or Latino20013
Not Hispanic or Latino434314
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDTotal
American Indian or Alaska Native00000
Asian10001
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White324413
More than one race00000
Unknown or Not Reported21003
Region of Enrollment
Region of Enrollment(Participants)LAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDTotal
United States634417
BMI
BMI(kg/m^2)LAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDTotal
Median32.4 (19 to 45)27.6 (26 to 29)27.5 (24 to 28)21.6 (20 to 48)27.6 (19 to 48)
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)LAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDTotal
0 = Fully active00011
1 = Restricted in physically strenuous activity but ambulatory521210
2 = Ambulatory and capable of all self-care but unable to carry out any work activities11316
Elevated peripheral blood AML blast %
Elevated peripheral blood AML blast %(percentage)LAM-003 200 mg QDLAM-003 300 mg QDLAM-003 450 mg QDLAM-003 600 mg QDTotal
Median24.75 (2.9 to 89.3)41.40 (13.6 to 95.1)22.15 (11.9 to 74.0)34.05 (4.5 to 97.1)30.40 (2.9 to 97.1)

1 further baseline measures are reported on the registry.

09

Study locations

6 sites
  • Yale University
    New Haven, Connecticut 06511, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Hackensack Meridien Health
    Hackensack, New Jersey 07601, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Feb 2020, 25 months.

Results were first posted in May 2024, 4 years 2 months after primary completion.

Of 182 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 25 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2018
First posted
Feb 8, 2018
StartActual
Jan 16, 2018
Primary completionActual
Feb 20, 2020
CompletionActual
Oct 5, 2020
Results first posted
May 3, 2024
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03426605
Lead sponsor
OrphAI Therapeutics
Responsible party
Sponsor
First posted
Feb 8, 2018
Start date
Jan 16, 2018
Primary completion
Feb 20, 2020
Completion
Oct 5, 2020
Results posted
May 3, 2024
Last update
May 3, 2024

Study contacts

Langdon Miller, M.D.
study director · AI Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion